https://www.selleckchem.com/products/ms4078.html
Oral corticosteroids (OCS) carry serious health risks. Innovative treatment options are required to reduce excessive exposure and promote OCS stewardship. This study evaluated the trajectories of OCS exposure (prednisolone-equivalent) in patients with severe eosinophilic asthma before and after starting mepolizumab and the predictors of becoming OCS free after 6 months of mepolizumab therapy. This real-world observational study included 309 patients from the Australian Mepolizumab Registry who were followed up for 1 year (n= 225). Patien
Like
Comment
Share
